Return to List

Study Summary
No. 2004-0606:.......Head And Neck......Merrill S. Kies......Thoracic and Head and Neck Med
.
Study Summary Title
Study Summary
Number:
2004-0606
Study Title:Phase 2 study of the Anti-Angiogenesis Agent AG-013736 in Patients with Metastatic Thyroid Cancer who are Refractory to or not Suitable Candidates for 131 I Treatment
.
Physician New Patient Referral
Name:Merrill S. KiesPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:Thoracic and Head and Neck MedReferring MD
Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-792-6363
Contact us about clinical trials
.
General Information
Disease Group:Head And NeckSupported By:N/A
Phase of Study:Phase IIReturn
Visit:
Every 4 weeks
Treatment
Agents:
AG013736Home Care:N/A
Treatment Loc:Independent Multicenter Arrangements
Estimated
Length of Stay
in Houston:
N/A
Description/
Intervention:
The goal of this clinical research study is to learn if AG-013736 can shrink or
slow the growth of thyroid cancer. The safety of this drug will also be
studied.
.
Study Objectives / Outcomes
The primary objective of this study is to determine the response rate of AG-013736 in patients with metastatic thyroid cancer who are refractory to or not suitable candidates for 131I treatment as measured by the overall response rate, complete response (CR) and partial response (PR) by RECIST.
Secondary objectives with are to:
determine the safety profile of AG-013736
determine progression-free survival (PFS)
determine duration of response
determine overall survival
obtain blood samples for population pharmacokinetic analyses (optional)
explore relationships between clinical response and plasma soluble proteins
.
Study Status Information
Study Activation / Registration Date:02/10/2006
IRB Review and Approval Date:12/15/2004
Study Type:Therapeutic
Recruitment Status:Closed
Projected Accrual:60
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.

Inclusion Criteria:1) Histologically documented thyroid cancer with metastases.

2) Failure of 131I to control the disease or 131I is not an appropriate therapy (eg, due to lack of iodine uptake by the tumor).

3) No expectation of further effects of prior anticancer therapy.

4) At least 1 target lesion, as defined by RECIST, that has not been irradiated. New lesions that have developed in a previously irradiated field may be used as sites of measurable disease assuming all other criteria are met. All target lesions must have a unidimensional diameter of at least 2 cm. (1 cm is acceptable for spiral CT scans if the reconstruction algorithm is 0.5 cm). Baseline measurements/evaluations must be completed within 4 weeks prior to treatment.

5) Adequate bone marrow, hepatic, and renal function documented within 14 days prior to treatment as documented by: absolute neutrophil count (ANC, calculated as the absolute number of neutrophils and bands) >/=1.5 x 10^9 cells/L; platelets >/=100 x 10^9 cells /L; AST and ALT </= 2.5 x upper limit of normal, unless there are liver metastases in which case AST and ALT </= 5.0 x ULN; total bilirubin </= 1.5 x ULN;serum creatinine </= 1.5 x ULN or calculated creatinine clearance >/= 60 mL/min;

6) urinary protein <2+ by urine dipstick. If dipstick is >/= 2+ then a 24-hour urine collectioncan be done and the patient may enter only if urinary protein is <2 g per 24 hours

7) Age >/= 18 years

8) ECOG performance status of 0 or 1

9) No evidence of preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart. The baseline systolic blood pressure readings must be </= 140, and the baseline diastolic blood pressure readings must be </= 90. Patients whose hypertension is controlled by antihypertensive therapies are eligible.

10) Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to treatment.

11) Written and voluntary informed consent.

Exclusion Criteria:1) Central lung lesions involving major blood vessels (arteries or veins). (Central lesions that maintain the structural integrity of vessels have the potential to bleed if the tumor lesion undergoes necrosis. MRI or CT angiography should be used in any case where there is any question as to whether blood vessels are involved.)

2) History of hemoptysis

3) Gastrointestinal abnormalities including: inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including gastric resection; treatment for active peptic ulcer disease in the past 6 months; active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy; malabsorption syndromes.

4) Previous treatment with anti-angiogenesis agents including thalidomide, or inhibitors of epidermoid growth factor (EGF), platelet derived growth factor (PDGF), or fibroblast growth factors (FGF) receptors.

5) Current use or anticipated inability to avoid use of drugs that are known potent CYP3A4 inhibitors (ie, grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole,erythromycin, clarithromycin, ergot derivatives, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, and delavirdine).

6) Current use or anticipated inability to avoid use of drugs that are known CYP3A4 or CYP1A2 inducers (ie, carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, primidone, rifabutin, rifampin, and St. John's wort).

7) Active seizure disorder or evidence of brain metastases.

8) A serious uncontrolled medical disorder or active infection that would impair their ability to receive study treatment.

9) History of a malignancy (other than thyroid cancer) except those treated with curative intent for skin cancer (other than melanoma) or in situ breast or cervical cancer or those treated with curative intent for any other cancer with no evidence of disease for 5 years

10) Major surgical procedure or any radiation therapy within 4 weeks of treatment.

11) Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.

12) Patients (male and female) having procreative potential who are not using adequate contraception or practicing abstinence

13) Women who are pregnant or breast-feeding.

.
Links
Registration Number: NCT00094055
Study Information on Clinical Trials Registry (clinicaltrials.gov)

Other Links:
.
Results


Return to Clinical Trials at M.D. Anderson Cancer Center